Treats major depressive disorder (MDD). ANDA 204083, held by Hikma Pharmaceuticals. Desvenlafaxine Succinate.
As of Nov 22, 2026, ANDA 204083 (Desvenlafaxine Succinate), held by Hikma Pharmaceuticals, was first approved by FDA on Feb 16, 2016, with 6 approved supplements and 0 published complete response letters.
Desvenlafaxine is indicated for the treatment of adults with major depressive disorder (MDD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 16, 2016 | Original application | Approved |
| Desvenlafaxine SuccinateEQ 100MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 25MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Desvenlafaxine SuccinateEQ 50MG BASE · tablet, extended release;oral | Desvenlafaxine Succinate | Rx |
| Sep 4, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 4, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 4, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 30, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 5, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 6, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 16, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters